Can you create a table summarizing the changes in cervical cancer screening guidelines, including age groups, screening methods, and screening intervals?

Cervical Cancer Screening Guideline Changes: ACS 2012 vs 2020

The American Cancer Society fundamentally shifted cervical cancer screening in 2020 by raising the starting age from 21 to 25 years and making primary HPV testing the preferred method starting at age 25, replacing the previous age-stratified approach that used cytology alone until age 30. 1

Summary Table: Key Changes Between ACS 2012 and 2020 Guidelines

Population	ACS 2012	ACS 2020	Key Change
Age <25 years	Cytology alone every 3 years starting at age 21	No screening	Screening start age raised from 21 to 25 years
Age 25-29 years	Cytology alone every 3 years	Primary HPV testing every 5 years (preferred) OR Cotesting every 5 years OR Cytology alone every 3 years (acceptable)	HPV testing now available starting at age 25 (previously only at age 30+)
Age 30-65 years	Cotesting every 5 years (preferred) OR Cytology alone every 3 years (acceptable) Primary HPV testing NOT recommended	Primary HPV testing every 5 years (preferred) OR Cotesting every 5 years OR Cytology alone every 3 years (acceptable)	Primary HPV testing now preferred method Cotesting downgraded from preferred to acceptable
Age >65 years	Discontinue screening after adequate negative prior screening	Discontinue screening if: • No CIN2+ in past 25 years, AND • Adequate negative screening in past 10 years Adequate = 2 consecutive negative HPV tests OR 2 negative cotests OR 3 negative cytology tests	More specific cessation criteria defined
After hysterectomy	No screening after hysterectomy for non-cancer reasons	No screening if cervix removed AND no CIN2+ history in past 25 years	Essentially unchanged
HPV vaccinated	Follow age-specific recommendations	Follow age-specific recommendations (same as unvaccinated)	No change

Critical Implementation Points

Four Major Paradigm Shifts 1

1. Primary HPV testing is now the preferred strategy (previously not recommended for most settings)
2. Screening starts at age 25, not 21 (eliminates 4 years of screening in young women)
3. HPV testing available from age 25 onward (previously restricted to age 30+)
4. Transitional guideline: Cotesting and cytology alone are acceptable only where FDA-approved primary HPV testing is unavailable and will be phased out in future guidelines

Rationale for Changes

Why delay screening to age 25? 1

• Cervical cancer is extremely rare in women under 25
• High rates of transient HPV infections in younger women lead to unnecessary colposcopies and treatments
• Excisional treatments increase preterm birth risk by 70% 2

Why prefer primary HPV testing? 1

• Superior sensitivity for detecting high-grade precancers
• Better negative predictive value allows safer 5-year intervals
• More efficient in HPV-vaccinated populations (cytology increasingly detects false-positives as cancer rates decline)
• Only 2 FDA-approved primary HPV tests currently available, both approved for age 25+ 1

Common Pitfalls to Avoid

⚠️ Do NOT screen more frequently than recommended intervals - Annual screening at any age with any method is explicitly discouraged 1

⚠️ Do NOT use primary HPV testing under age 25 - Not FDA-approved and will detect transient infections requiring unnecessary follow-up 1

⚠️ Do NOT continue cytology-only screening if primary HPV testing is accessible - This is a transitional accommodation only 1

⚠️ Do NOT stop screening at age 65 without documented adequate prior screening - Continue screening until cessation criteria are met 1

Screening Cessation Criteria (Age >65)

Must meet BOTH conditions: 1

• No history of CIN2+ in past 25 years, AND
• Documented adequate negative screening in past 10 years:
  • 2 consecutive negative primary HPV tests, OR
  • 2 consecutive negative cotests, OR
  • 3 consecutive negative cytology tests
  • With most recent test within recommended interval (3-5 years depending on test)

Management of Abnormal Results

All positive screening results should be managed according to the 2019 ASCCP Risk-Based Management Consensus Guidelines 1 - not covered in this screening guideline.

Alignment with Other Guidelines

The 2018 USPSTF guidelines 3 differ slightly:

• USPSTF still recommends starting screening at age 21 (not 25)
• USPSTF includes primary HPV testing as co-equal option (not preferred) for ages 30-65
• Otherwise screening intervals and methods align

This represents the most significant evolution in cervical cancer screening since widespread cytology implementation in the 1950s, driven by superior HPV test performance and recognition of screening harms in young women. 1